Article Details

Phase 1 Trials Assess Safety, Dosing of CAL-R Antibody for Essential Thrombocythemia

Retrieved on: 2025-06-25 21:04:05

Tags for this article:

Click the tags to see associated articles and topics

Phase 1 Trials Assess Safety, Dosing of CAL-R Antibody for Essential Thrombocythemia. View article details on hiswai:

Excerpt

He presented these data, as summarized in the abstract titled, “INCA33989 is a Novel, First in Class, Mutant Calreticulin-Specific Monoclonal Antibody ...

Article found on: www.ajmc.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo